Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$32.02 +7.6%	$23.80	$16.50 ▼ $32.15	$2.79B	N/A	55,906 shs	20,376 shs
APLS Apellis Pharmaceuticals	$19.26 -0.1%	$18.31	$16.10 ▼ $43.61	$2.42B	0.68	2.33 million shs	1.30 million shs
OGN Organon & Co.	$10.07 -0.1%	$10.16	$8.01 ▼ $23.10	$2.62B	0.58	3.41 million shs	4.40 million shs
XNCR Xencor	$9.43 -0.9%	$9.03	$7.16 ▼ $27.24	$677.55M	0.87	667,127 shs	451,862 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-0.50%	+5.16%	+22.93%	+59.69%	+2,974,999,900.00%
APLS Apellis Pharmaceuticals	-1.58%	+4.11%	+9.99%	-20.93%	-54.92%
OGN Organon & Co.	+0.70%	+5.92%	+16.26%	-32.48%	-50.15%
XNCR Xencor	-2.26%	+4.62%	+8.55%	-26.03%	-56.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	4.7688 of 5 stars	4.3	3.0	0.0	4.4	3.9	2.5	0.6
OGN Organon & Co.	4.7997 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	3.1
XNCR Xencor	4.1903 of 5 stars	3.4	2.0	0.0	3.9	3.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	107.96% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	78.75% Upside
XNCR Xencor	2.89	Moderate Buy	$29.50	212.83% Upside

Current Analyst Ratings Breakdown

Latest XNCR, AAPG, OGN, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/8/2025	APLS Apellis Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $18.00
5/8/2025	APLS Apellis Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$28.00 ➝ $20.00
5/8/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $26.00
5/8/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$55.00 ➝ $47.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	2.84	N/A	N/A	N/A	∞
APLS Apellis Pharmaceuticals	$775.84M	3.12	N/A	N/A	$1.64 per share	11.74
OGN Organon & Co.	$6.29B	0.42	$3.23 per share	3.12	($0.27) per share	-37.30
XNCR Xencor	$127.23M	5.28	N/A	N/A	$10.99 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	-$528.63M	-$1.79	N/A	N/A	N/A	-34.97%	-103.11%	-28.96%	7/30/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.02	2.69	0.90	13.49%	431.62%	8.03%	8/5/2025 (Estimated)
XNCR Xencor	-$126.09M	-$3.06	N/A	N/A	N/A	-232.77%	-30.92%	-21.74%	8/4/2025 (Estimated)

Latest XNCR, AAPG, OGN, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.79%	N/A	2.78%	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Latest XNCR, AAPG, OGN, and APLS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	1.91	4.36	3.73
OGN Organon & Co.	17.73	1.70	1.21
XNCR Xencor	0.01	6.23	6.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
APLS Apellis Pharmaceuticals	96.29%
OGN Organon & Co.	77.43%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
APLS Apellis Pharmaceuticals	6.50%
OGN Organon & Co.	1.96%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.11 million	N/A	N/A
APLS Apellis Pharmaceuticals	770	125.68 million	115.93 million	Optionable
OGN Organon & Co.	10,000	259.96 million	253.93 million	Not Optionable
XNCR Xencor	280	71.17 million	66.32 million	Optionable

XNCR, AAPG, OGN, and APLS Headlines

Recent News About These Companies

Analysts Set Xencor, Inc. (NASDAQ:XNCR) Target Price at $29.50

June 11 at 3:41 AM | americanbankingnews.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10 at 1:04 PM | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9 at 3:08 AM | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Holdings in Xencor, Inc. (NASDAQ:XNCR)

June 3, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Two Sigma Investments LP

May 27, 2025 | marketbeat.com

Nuveen Asset Management LLC Purchases 685,557 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 26, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC

May 26, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by RTW Investments LP

May 18, 2025 | marketbeat.com

Point72 Asset Management L.P. Sells 943,148 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 18, 2025 | marketbeat.com

Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)

May 17, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by Brokerages

May 16, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)

May 15, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings

May 13, 2025 | marketbeat.com

Wedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)

May 13, 2025 | marketbeat.com

Research Analysts Set Expectations for Xencor Q2 Earnings

May 13, 2025 | marketbeat.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Analysts Say Unilever Has the Leverage to Hit New Highs
By Thomas Hughes | May 15, 2025
View Analysts Say Unilever Has the Leverage to Hit New Highs

XNCR, AAPG, OGN, and APLS Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$32.02 +2.27 (+7.63%)

As of 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Apellis Pharmaceuticals NASDAQ:APLS

$19.26 -0.01 (-0.05%)

As of 04:00 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Organon & Co. NYSE:OGN

$10.07 -0.01 (-0.10%)

As of 03:59 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Xencor NASDAQ:XNCR

$9.43 -0.09 (-0.95%)

As of 04:00 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time